Financials data is unavailable for this security.
Cash flow in USDView more
In 2024, Estrella Immunopharma Inc increased its cash reserves by 68.02%, or 1.69m. Cash Flow from Financing totalled 12.79m or -- of revenues. In addition the company used 16.07m for operations while cash from investing totalled 4.96m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1178 |
---|---|
Tangible book value per share | 0.1178 |
More ▼
Balance sheet in USDView more
Current ratio | 24.65 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼